Posts Archive

MagnetisMM-9 NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That...

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...

REST NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST) Newly diagnosed multiple myeloma patients...

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma This study will assess...

NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM As optimal...

NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies GEN3014 Safety Trial in Relapsed or...

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma Blood Cancer J; 2021...

SABLe NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

NCT04855929: Phase 1: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma....

Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in...

NCT04570631: Phase 1: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or...

NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple...

NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON) Iberdomide Combined With Low-dose...

IONA-MM NCT04458831: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory...

NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM to Proteasome Inhibitors, Immunomodulators and Anti-CD38...

CAEL-101 Amy NCT04512235: Phase 3: A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL...

NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma...